156 related articles for article (PubMed ID: 18322685)
1. Serum antibodies against Saccharomyces cerevisiae: a new prognostic indicator in metastatic renal-cell carcinoma.
Ramoner R; Rahm A; Gander H; Stollenwerk B; Falkensammer C; Leonhartsberger N; Thurnher M
Cancer Immunol Immunother; 2008 Aug; 57(8):1207-14. PubMed ID: 18322685
[TBL] [Abstract][Full Text] [Related]
2. Serum IgG against Candida predict survival in patients with metastatic renal cell carcinoma.
Ramoner R; Rahm A; Falkensammer CE; Leonhartsberger N; Thurnher M
Cancer Immunol Immunother; 2010 Aug; 59(8):1141-7. PubMed ID: 20182873
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
4. Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy.
Tsujino T; Komura K; Matsunaga T; Yoshikawa Y; Takai T; Uchimoto T; Saito K; Tanda N; Oide R; Minami K; Uehara H; Jeong SH; Taniguchi K; Hirano H; Nomi H; Ibuki N; Takahara K; Inamoto T; Azuma H
Ann Surg Oncol; 2017 Sep; 24(9):2787-2793. PubMed ID: 28643013
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of hemoglobin-to-red cell distribution width ratio in patients with metastatic renal cancer.
Yılmaz H; Yılmaz A; Demirağ G
Future Oncol; 2021 Oct; 17(29):3853-3864. PubMed ID: 34382414
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
[TBL] [Abstract][Full Text] [Related]
7. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
[TBL] [Abstract][Full Text] [Related]
9. High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker.
Väänänen T; Kallio J; Vuolteenaho K; Ojala A; Luukkaala T; Hämäläinen M; Tammela T; Kellokumpu-Lehtinen PL; Moilanen E
Scand J Urol; 2017 Oct; 51(5):367-372. PubMed ID: 28644702
[TBL] [Abstract][Full Text] [Related]
10. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial.
Patel A; Ravaud A; Motzer RJ; Pantuck AJ; Staehler M; Escudier B; Martini JF; Lechuga M; Lin X; George DJ
Clin Cancer Res; 2020 Sep; 26(18):4863-4868. PubMed ID: 32546645
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.
Alamdari FI; Rasmuson T; Grankvist K; Ljungberg B
Scand J Urol Nephrol; 2007; 41(1):5-9. PubMed ID: 17366095
[TBL] [Abstract][Full Text] [Related]
14. Pretherapeutic Plasma Fibrinogen Level is an Independent Survival Predictor in Renal Cell Carcinoma.
Sasaki T; Onishi T
Oncol Res Treat; 2015; 38(7-8):374-8. PubMed ID: 26278582
[TBL] [Abstract][Full Text] [Related]
15. Role of circulating tumor cells in patients with metastatic clear-cell renal cell carcinoma.
Nayak B; Panaiyadiyan S; Singh P; Karmakar S; Kaushal S; Seth A
Urol Oncol; 2021 Feb; 39(2):135.e9-135.e15. PubMed ID: 33250345
[TBL] [Abstract][Full Text] [Related]
16. The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma.
Sengupta S; Lohse CM; Cheville JC; Leibovich BC; Thompson RH; Webster WS; Frank I; Zincke H; Blute ML; Kwon ED
Cancer; 2006 Jan; 106(2):304-12. PubMed ID: 16353202
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of the combination of preoperative hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) in patients with renal cell carcinoma after nephrectomy.
Peng D; Zhang CJ; Tang Q; Zhang L; Yang KW; Yu XT; Gong Y; Li XS; He ZS; Zhou LQ
BMC Urol; 2018 Mar; 18(1):20. PubMed ID: 29544476
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum-gamma-glutamyltransferase (GGT) does not represent an independent prognostic factor in a European cohort of patients with non-metastatic renal cell carcinoma.
Dalpiaz O; Pichler M; Mrsic E; Reitz D; Krieger D; Venturino L; Bezan A; Stojakovic T; Pummer K; Zigeuner R; Hutterer GC
J Clin Pathol; 2015 Jul; 68(7):547-51. PubMed ID: 25862811
[TBL] [Abstract][Full Text] [Related]
20. Preoperative Neutrophil-lymphocyte Ratio as a Predictor of Overall Survival in Patients with Localized Renal Cell Carcinoma.
Widz D; Mitura P; Buraczynski P; Plaza P; Bar M; Cabanek M; Nowak G; Ostrowska A; Bar K
Urol J; 2020 Jan; 17(1):30-35. PubMed ID: 31087321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
